Claudio Rapezzi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6796960/publications.pdf

Version: 2024-02-01

275 papers	25,932 citations	16451 64 h-index	6996 154 g-index
291 all docs	291 docs citations	291 times ranked	16176 citing authors

#	Article	IF	Citations
1	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	2.2	3,469
2	Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. European Heart Journal, 2007, 29, 270-276.	2.2	2,280
3	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2018, 379, 1007-1016.	27.0	1,558
4	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
5	A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM) Tj ETQq1 1 0.784314 rgBT /Overl	2.2	848
6	Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy. Circulation, 2014, 130, 484-495.	1.6	783
7	Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99m Tc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy. Journal of the American College of Cardiology, 2005, 46, 1076-1084.	2.8	674
8	Systemic Cardiac Amyloidoses. Circulation, 2009, 120, 1203-1212.	1.6	622
9	Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet Journal of Rare Diseases, 2013, 8, 31.	2.7	525
10	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	2.2	434
11	Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2010, 31, 2715-2726.	2.2	408
12	Long-Term Safety of Drug-Eluting andÂBare-Metal Stents. Journal of the American College of Cardiology, 2015, 65, 2496-2507.	2.8	396
13	Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 1448-1458.	2.2	346
14	Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet, The, 2015, 385, 2371-2382.	13.7	345
15	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, 2016, 68, 161-172.	2.8	338
16	Long-Term Outcome and Risk Stratification in Dilated Cardiolaminopathies. Journal of the American College of Cardiology, 2008, 52, 1250-1260.	2.8	335
17	Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation, 2017, 135, 1357-1377.	1.6	319
18	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation: Heart Failure, 2019, 12, e006075.	3.9	312

#	Article	IF	Citations
19	Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy. Circulation, 2009, 119, 1703-1710.	1.6	296
20	Transthyretin-related amyloidoses and the heart: a clinical overview. Nature Reviews Cardiology, 2010, 7, 398-408.	13.7	286
21	Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac Amyloidosis. Circulation, 2014, 129, 1840-1849.	1.6	274
22	Role of 99mTc-DPD Scintigraphy in Diagnosis and Prognosis of Hereditary Transthyretin-Related Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2011, 4, 659-670.	5.3	264
23	Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. European Heart Journal, 2017, 38, 1895-1904.	2.2	258
24	Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. European Heart Journal, 2013, 34, 520-528.	2.2	252
25	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	2.1	230
26	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 553-576.	7.1	224
27	Dilated-Hypokinetic Evolution of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2005, 46, 1543-1550.	2.8	199
28	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. European Heart Journal, 2007, 29, 277-278.	2.2	190
29	Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC: Heart Failure, 2019, 7, 709-716.	4.1	188
30	Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 470-478.	6.4	175
31	Short- Versus Long-Term DualÂAntiplateletÂTherapy After Drug-ElutingÂStent Implantation. Journal of the American College of Cardiology, 2015, 65, 1092-1102.	2.8	163
32	Clinical Relevance of Atrial Fibrillation/Flutter, Stroke, Pacemaker Implant, and Heart Failure in Emery-Dreifuss Muscular Dystrophy. Stroke, 2003, 34, 901-908.	2.0	158
33	Cardiac amyloidosis: the great pretender. Heart Failure Reviews, 2015, 20, 117-124.	3.9	147
34	Precipitating factors and decision-making processes of short-term worsening heart failure despite â€œoptimalâ€•treatment (from the IN-CHF Registry). American Journal of Cardiology, 2001, 88, 382-387.	1.6	131
35	Heart failure with preserved ejection fraction: uncertainties and dilemmas. European Journal of Heart Failure, 2015, 17, 665-671.	7.1	124
36	Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 147-155.	3.0	115

#	Article	IF	Citations
37	Prediction of thromboâ€embolic risk in patients with hypertrophic cardiomyopathy (<scp>HCM</scp>) Tj ETQq1 1 0.784314 rgBT /Over	7.1	114
38	Risk of Sudden Death and Outcome in Patients With Hypertrophic Cardiomyopathy With Benign Presentation and Without Risk Factors. American Journal of Cardiology, 2014, 113, 1550-1555.	1.6	107
39	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	1.7	107
40	Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 142-150.	3.0	106
41	Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. European Journal of Heart Failure, 2020, 22, 507-515.	7.1	106
42	Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). European Heart Journal, 2022, 43, 391-400.	2.2	105
43	Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2016, 9, .	3.9	103
44	Different Types of Cardiomyopathy Associated With Isolated Ventricular Noncompaction. American Journal of Cardiology, 2006, 98, 821-824.	1.6	102
45	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€"Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	2.1	97
46	Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. American Heart Journal, 1998, 136, 824-830.	2.7	96
47	Prognostic Implications of the Doppler Restrictive Filling Pattern in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2009, 104, 1727-1731.	1.6	93
48	Atherosclerotic aortic lesions increase the risk of cerebral embolism during carotid stenting in patients with complex aortic arch anatomy. Journal of Vascular Surgery, 2009, 49, 80-85.	1.1	93
49	Identification ofÂTTR-Related Subclinical Amyloidosis WithÂ99mTc-DPD Scintigraphy. JACC: Cardiovascular Imaging, 2014, 7, 531-532.	5.3	91
50	Coexistence of Degenerative Aortic Stenosis and Wild-Type Transthyretin-Related CardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2016, 9, 325-327.	5.3	89
51	Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 40-48.	3.0	83
52	State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. Journal of Nuclear Cardiology, 2019, 26, 158-173.	2.1	82
53	Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1314-1321.	5.3	82
54	Left atrial structure and function in cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2017, 18, 1128-1137.	1.2	80

#	Article	IF	Citations
55	Role of 18F-FDG PET/CT in the diagnosis of infective endocarditis in patients with an implanted cardiac device: a prospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1617-1623.	6.4	79
56	Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events. JAMA Cardiology, 2018, 3, 520.	6.1	78
57	Myocarditis in COVID-19 patients: current problems. Internal and Emergency Medicine, 2021, 16, 1123-1129.	2.0	78
58	Significance of Sarcomere Gene Mutations Analysis in the End-Stage Phase of Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2014, 114, 769-776.	1.6	76
59	The spectrum of myocarditis: from pathology to the clinics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 279-301.	2.8	73
60	Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart, 2017, 103, 672-678.	2.9	71
61	Heart Transplantation in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2008, 101, 387-392.	1.6	70
62	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	1.7	70
63	Transesophageal echocardiographyâ€"guided algorithm for stent-graft implantation in aortic dissection. Journal of Vascular Surgery, 2004, 40, 880-885.	1.1	69
64	Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. JAMA Cardiology, 2020, 5, 73.	6.1	69
65	Clinical Importance of Left Atrial Infiltration in Cardiac TransthyretinÂAmyloidosis. JACC: Cardiovascular Imaging, 2022, 15, 17-29.	5.3	67
66	Primary endoleakage in endovascular treatment of the thoracic aorta: Importance of intraoperative transesophageal echocardiography. Journal of Thoracic and Cardiovascular Surgery, 2000, 120, 490-495.	0.8	65
67	The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. Heart Rhythm, 2020, 17, 142-151.	0.7	65
68	Usefulness of transesophageal echocardiographic monitoring to improve the outcome of stent-graft treatment of thoracic aortic aneurysms. American Journal of Cardiology, 2001, 87, 315-319.	1.6	64
69	Usefulness of 99mTc-DPD Scintigraphy in Cardiac Amyloidosis. Journal of the American College of Cardiology, 2008, 51, 1509-1510.	2.8	64
70	Risk Factors for Diagnostic Delay in Acute Aortic Dissection. American Journal of Cardiology, 2008, 102, 1399-1406.	1.6	63
71	18F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1190-1196.	6.4	63
72	Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart, 2016, 3, e000289.	2.3	62

#	Article	IF	Citations
73	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 2020, 21, 198.	2.9	60
74	Significance of Magnetic Resonance Imaging in Apical Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2010, 105, 1592-1596.	1.6	59
75	Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy) Tj ETQq1 1 0.784314 rgBT /Ov	3.9	59
76	Transcatheter Mitral Valve Repair in Cardiogenic Shock and Mitral Regurgitation. JACC: Cardiovascular Interventions, 2021, 14, 1-11.	2.9	59
77	Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: Towards tailoring of therapeutic strategies?. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2006, 13, 143-153.	3.0	57
78	Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 2021, 23, 895-905.	7.1	57
79	The Italian registry for hypertrophic cardiomyopathy: A nationwide survey. American Heart Journal, 2005, 150, 947-954.	2.7	56
80	Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: Long-term follow-up of the SHIRAKISS randomized, prospective study. Journal of Heart and Lung Transplantation, 2012, 31, 565-570.	0.6	56
81	Effects of cardiac resynchronisation therapy on dilated cardiomyopathy with isolated ventricular non-compaction. Heart, 2011, 97, 295-300.	2.9	55
82	Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 143-155.	3.0	55
83	Seven-year follow-up after dobutamine stress echocardiography. Journal of the American College of Cardiology, 2005, 45, 93-97.	2.8	52
84	The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy. European Journal of Heart Failure, 2020, 22, 1097-1107.	7.1	52
85	Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy. JACC: Heart Failure, 2021, 9, 115-123.	4.1	52
86	Exercise stress echocardiography is superior to rest echocardiography in predicting left ventricular reverse remodelling and functional improvement after cardiac resynchronization therapy. European Heart Journal, 2008, 30, 89-97.	2.2	51
87	ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 259-265.	3.0	51
88	Redefining the epidemiology of cardiac amyloidosis. A systematic review and metaâ€analysis of screening studies. European Journal of Heart Failure, 2022, 24, 2342-2351.	7.1	51
89	Accuracy of non-invasive techniques for diagnosis of coronary artery disease and prediction of cardiac events in patients with left bundle branch block: a meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1442-1451.	6.4	50
90	Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis â€“ Report from the Transthyretin Amyloidosis Outcome Survey (THAOS). PLoS ONE, 2017, 12, e0173086.	2.5	50

#	Article	IF	Citations
91	Paradoxical Contributions of Non-Compacted and Compacted Segments to Global Left Ventricular Dysfunction in Isolated Left Ventricular Noncompaction. American Journal of Cardiology, 2006, 97, 738-741.	1.6	49
92	Cardiac Resynchronization Therapy: Variations in Echo-Guided Optimized Atrioventricular and Interventricular Delays During Follow-Up. Echocardiography, 2007, 24, 933-939.	0.9	49
93	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	2.6	48
94	Short- and Long-Term Prognostic Significance of ST-Segment Elevation in Lead aVR in Patients With Nonâ€"ST-Segment Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2011, 108, 21-28.	1.6	47
95	Interplay of coronary angiography and intravascular ultrasound in predicting long-term outcomes after heart transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 1146-1153.	0.6	45
96	Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2016, 118, 432-439.	1.6	45
97	Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: Time courses and prediction of response. Peptides, 2006, 27, 1776-1786.	2.4	44
98	Predictors of long-term survival free from relapses after extraction of infected CIED. Europace, 2018, 20, 1018-1027.	1.7	43
99	The role of physical activity in individuals with cardiovascular risk factors: an opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport. Journal of Cardiovascular Medicine, 2019, 20, 631-639.	1.5	43
100	Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the <scp>ACâ€TIVE</scp> study, an <scp>Italian nationwide survey</scp>. European Journal of Heart Failure, 2022, 24, 1377-1386.	7.1	43
101	Cardiac resynchronization by pacing: an electrical treatment of heart failure. International Journal of Cardiology, 2004, 94, 151-161.	1.7	40
102	Risk of Adverse Cardiac and Bleeding Events Following Cardiac and Noncardiac Surgery in Patients With Coronary Stent. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 39-47.	2.2	40
103	Assessment of patients with hereditary transthyretin amyloidosis â€" understanding the impact of management and disease progression. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 103-111.	3.0	40
104	Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis. International Journal of Cardiology, 2017, 243, 379-384.	1.7	39
105	Prognostic significance of mean platelet volume on admission in an unselected cohort of patients with non ST-segment elevation acute coronary syndrome. Thrombosis and Haemostasis, 2011, 106, 132-140.	3.4	38
106	Multimodality imaging in cardiac amyloidosis: a primer for cardiologists. European Heart Journal Cardiovascular Imaging, 2020, 21, 833-844.	1.2	38
107	Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 12-18.	3.0	38
108	New pathological insights into cardiac amyloidosis: implications for non-invasive diagnosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 99-105.	3.0	36

#	Article	IF	Citations
109	Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure. European Journal of Heart Failure, 2018, 20, 1417-1425.	7.1	36
110	Ventricular remodeling in Loeffler endocarditis: Implications for therapeutic decision making. European Journal of Heart Failure, 2005, 7, 1023-1026.	7.1	35
111	Anticoagulant drugs in noncompaction: a mandatory therapy?. Journal of Cardiovascular Medicine, 2008, 9, 1095-1097.	1.5	35
112	The elusive link between aortic wall histology and echocardiographic anatomy in bicuspid aortic valve: implications for prophylactic surgery. European Journal of Cardio-thoracic Surgery, 2012, 41, 322-327.	1.4	35
113	Critical Comparison of Documents FromÂScientific Societies on CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2022, 79, 1288-1303.	2.8	35
114	Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis. European Journal of Internal Medicine, 2020, 80, 66-72.	2.2	34
115	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2021, 28, 1769-1774.	2.1	34
116	Left ventricular rotational mechanics in patients with coronary artery disease: differences in subendocardial and subepicardial layers. Heart, 2010, 96, 1737-1743.	2.9	33
117	Defining the Diagnosis in Echocardiographically Suspected Senile Systemic Amyloidosis. JACC: Cardiovascular Imaging, 2012, 5, 755-758.	5.3	33
118	Combined computed tomography and fluorodeoxyglucose positron emission tomography in the diagnosis of prosthetic valve endocarditis: a case series. BMC Research Notes, 2014, 7, 32.	1.4	32
119	Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery. European Journal of Internal Medicine, 2020, 82, 7-15.	2.2	32
120	Prognostic Significance of Left Anterior Hemiblock in Patients With Suspected Coronary Artery Disease. Journal of the American College of Cardiology, 2005, 46, 858-863.	2.8	31
121	Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT?. Journal of Nuclear Cardiology, 2017, 24, 746-749.	2.1	31
122	Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart, 2019, 105, heartjnl-2018-313700.	2.9	31
123	Outcome of cardioverterâ€"defibrillator implant in patients with arrhythmogenic right ventricular cardiomyopathy. Heart and Vessels, 2007, 22, 184-192.	1.2	30
124	Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy. Heart, 2017, 103, 300-306.	2.9	30
125	Frequency, Determinants, and Clinical Relevance of Acute Coronary Syndrome-Like Electrocardiographic Findings in Patients With Acute Aortic Syndrome. American Journal of Cardiology, 2007, 100, 1013-1019.	1.6	29
126	Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team. International Journal of Cardiology, 2020, 304, 86-92.	1.7	29

#	Article	IF	Citations
127	Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs. European Journal of Heart Failure, 2003, 5, 419-425.	7.1	28
128	White coats and fingerprints: diagnostic reasoning in medicine and investigative methods of fictional detectives. BMJ: British Medical Journal, 2005, 331, 1491-1494.	2.3	28
129	Incidence and risk factors for pacemaker implantation in lightâ€chain and transthyretin cardiac amyloidosis. European Journal of Heart Failure, 2022, 24, 1227-1236.	7.1	28
130	Troponin T elevation in acute aortic syndromes: Frequency and impact on diagnostic delay and misdiagnosis. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 61-71.	1.0	26
131	99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2021, 22, 1304-1311.	1.2	26
132	Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis. JACC: Heart Failure, 2021, 9, 736-746.	4.1	26
133	Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. European Journal of Heart Failure, 2022, 24, 1700-1712.	7.1	26
134	Atrial Fibrillation Precipitating Sustained Ventricular Tachycardia in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2002, 13, 954-954.	1.7	25
135	Ventricular dysfunction and number of non compacted segments in non compaction: Non-independent predictors. International Journal of Cardiology, 2010, 141, 250-253.	1.7	25
136	Cardiac involvement in hereditary-transthyretin related amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 16-21.	3.0	24
137	Idiopathic restrictive cardiomyopathy in the young: report of two cases. International Journal of Cardiology, 1990, 29, 121-126.	1.7	23
138	Relative Left Ventricular Apical Sparing of Longitudinal Strain in Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 1174-1176.	5.3	23
139	Analogies and disparities among scintigraphic bone tracers in the diagnosis of cardiac and non-cardiac ATTR amyloidosis. Journal of Nuclear Cardiology, 2019, 26, 1638-1641.	2.1	23
140	Systemic embolism in amyloid transthyretin cardiomyopathy. European Journal of Heart Failure, 2022, 24, 1387-1396.	7.1	23
141	Genotypic and phenotypic correlation in an Italian population of hereditary amyloidosis TTR-related (HA-TTR): clinical and neurophysiological aids to diagnosis and some reflections on misdiagnosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 58-60.	3.0	22
142	Diagnostic performance of standard electrocardiogram for prediction of infarct related artery and site of coronary occlusion in unselected STEMI patients undergoing primary percutaneous coronary intervention. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 326-339.	1.0	22
143	Incidence, treatment, and outcome of acute aortic valve regurgitation complicating percutaneous balloon aortic valvuloplasty. Catheterization and Cardiovascular Interventions, 2017, 89, E145-E152.	1.7	22
144	Redefining the histopathologic profile of acute aortic syndromes: Clinical and prognostic implications. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1776-1785.e6.	0.8	22

#	Article	IF	Citations
145	Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy. International Journal of Cardiology, 2019, 291, 77-82.	1.7	22
146	Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. Orphanet Journal of Rare Diseases, 2022, 17, .	2.7	22
147	Effect of Cardiac Resynchronization Therapy on Left Atrial Size and Function as Expressed by Speckle Tracking 2-Dimensional Strain. American Journal of Cardiology, 2016, 118, 237-243.	1.6	21
148	POPDC2 a novel susceptibility gene for conduction disorders. Journal of Molecular and Cellular Cardiology, 2020, 145, 74-83.	1.9	21
149	A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization â€" the first insight from the AC-TIVE Study. European Journal of Preventive Cardiology, 2022, 29, e173-e177.	1.8	21
150	Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC: CardioOncology, 2021, 3, 537-546.	4.0	21
151	Safety and efficacy of early aggressive versus cholesterol-driven lipid-lowering strategies in heart transplantation: A pilot, randomized, intravascular ultrasound study. Journal of Heart and Lung Transplantation, 2011, 30, 1305-1311.	0.6	20
152	The absence of dystrophin brain isoform expression in healthy human heart ventricles explains the pathogenesis of 5' X-linked dilated cardiomyopathy. BMC Medical Genetics, 2012, 13, 20.	2.1	20
153	Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis. Journal of Hypertension, 2014, 32, 1121-1131.	0.5	20
154	Brain Microbleeds 12ÂYears after Orthotopic Liver Transplantation in Val30Met Amyloidosis. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, e149-e151.	1.6	20
155	Targeted next-generation sequencing helps to decipher the genetic and phenotypic heterogeneity of hypertrophic cardiomyopathy. International Journal of Molecular Medicine, 2016, 38, 1111-1124.	4.0	20
156	The complex interplay among atherosclerosis, inflammation, and degeneration in ascending thoracic aortic aneurysms. Journal of Thoracic and Cardiovascular Surgery, 2020, 160, 1434-1443.e6.	0.8	20
157	The case against outpatient parenteral inotropic therapy for advanced heart failure. Journal of Heart and Lung Transplantation, 2000, 19, S58-S63.	0.6	19
158	Impact of high-sensitivity Troponin T on hospital admission, resources utilization, and outcomes. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 148-157.	1.0	19
159	Inverted U-Shaped Relation Between the Risk of Sudden Cardiac Death and Maximal Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	19
160	Left Ventricular versus Biventricular Pacing: A Randomized Comparative Study Evaluating Midâ€Term Electromechanical and Clinical Effects. Echocardiography, 2008, 25, 141-148.	0.9	18
161	Current patterns of betaâ€blocker prescription in cardiac amyloidosis: an Italian nationwide survey. ESC Heart Failure, 2021, 8, 3369-3374.	3.1	18
162	Effect of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe congestive heart failure: Improvement in hemodynamic and metabolic profile. Cardiovascular Drugs and Therapy, 1993, 7, 337-347.	2.6	17

#	Article	IF	Citations
163	Comparison of ventricular long-axis function in patients with cardiac amyloidosis versus idiopathic restrictive cardiomyopathy. American Journal of Cardiology, 2005, 95, 146-149.	1.6	17
164	Realâ€world versus trial patients with transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 2019, 21, 1479-1481.	7.1	17
165	Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery. ESC Heart Failure, 2022, 9, 751-760.	3.1	17
166	Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death. Expert Opinion on Investigational Drugs, 2007, 16, 605-623.	4.1	16
167	Cardiac resynchronization therapy in clinical practice: Need for electrical, mechanical, clinical and logistic synchronization. Journal of Interventional Cardiac Electrophysiology, 2007, 17, 215-224.	1.3	16
168	Arrhythmia discrimination by physician and defibrillator: Importance of atrial channel. International Journal of Cardiology, 2012, 154, 134-140.	1.7	16
169	High^{99m}Tc-DPD myocardial uptake in a patient with apolipoprotein AI-related amyloidotic cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 48-51.	3.0	16
170	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	2.6	16
171	Nuclear imaging for cardiac amyloidosis. Heart Failure Reviews, 2015, 20, 145-154.	3.9	15
172	Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, e212-e214.	1.6	15
173	Acute and chronic haemodynamic effects of biventricular pacing and of switching to different pacing modalities in heart failure patients. International Journal of Cardiology, 2006, 110, 318-323.	1.7	14
174	Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy. Journal of Cardiovascular Medicine, 2008, 9, 878-887.	1.5	14
175	Baseline White Blood Cell Count Is an Independent Predictor of Long-Term Cardiovascular Mortality in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome, but It Does Not Improve the Risk Classification of the GRACE Score. Cardiology, 2013, 124, 97-104.	1.4	14
176	Electrocardiographic Eligibility for Subcutaneous Implantable Cardioverter Defibrillator: Evaluation during Bicycle Exercise. Heart Lung and Circulation, 2016, 25, 476-483.	0.4	14
177	Intraoperative Diagnosis of Anderson-Fabry Disease in Patients With Obstructive Hypertrophic Cardiomyopathy Undergoing Surgical Myectomy. JAMA Cardiology, 2017, 2, 1147.	6.1	14
178	Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurology and Therapy, 2021, 10, 753-766.	3.2	14
179	Antisense Modulation of Both Exonic and Intronic Splicing Motifs Induces Skipping of a DMD Pseudo-Exon Responsible for X-Linked Dilated Cardiomyopathy. Human Gene Therapy, 2010, 21, 1137-1146.	2.7	13
180	The Mediterranean diet: a cultural journey. Lancet, The, 2011, 377, 1730-1731.	13.7	13

#	Article	IF	Citations
181	Effects of myocardial fibrosis assessed by MRI on dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: a retrospective database analysis. BMJ Open, 2012, 2, e001267.	1.9	13
182	Long-term prognostic role of cerebrovascular disease and peripheral arterial disease across the spectrum of acute coronary syndromes. Atherosclerosis, 2016, 245, 43-49.	0.8	13
183	Isolated ventricular non-compaction with restrictive cardiomyopathy. European Heart Journal, 2006, 27, 1927-1927.	2.2	12
184	Differences in cardiac phenotype and natural history of laminopathies with and without neuromuscular onset. Orphanet Journal of Rare Diseases, 2019, 14, 263.	2.7	12
185	Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy. Heart, 2022, 108, 54-60.	2.9	12
186	Transthyretin amyloidosis in aortic stenosis: clinical and therapeutic implications. European Heart Journal Supplements, 2021, 23, E128-E132.	0.1	12
187	How, Why, and When May Atrial Defibrillation Find a Specific Role in Implantable Devices? A Clinical Viewpoint. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 422-433.	1.2	11
188	The difficult diagnosis of isolated cardiac sarcoidosis: usefulness of an integrated MRI and PET approach. Heart, 2014, 100, 89-90.	2.9	11
189	The lack of effect of sotalol in short QT syndrome patients carrying the T618I mutation in the KCNH2 gene. HeartRhythm Case Reports, 2015, 1, 373-378.	0.4	11
190	Long-Term Outcomes and Causes of Death After Acute Coronary Syndrome in Patients in the Bologna, Italy, Area. American Journal of Cardiology, 2015, 115, 171-177.	1.6	11
191	Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach. Drugs, 2019, 79, 1543-1556.	10.9	11
192	Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis. Heart Failure Reviews, 2022, 27, 2187-2200.	3.9	11
193	Efficacy of internal cardioversion for chronic atrial fibrillation in patients with and without left ventricular dysfunction. International Journal of Cardiology, 2004, 95, 43-47.	1.7	10
194	Carotid Revascularization in Patients with Ongoing Oral Anticoagulant Therapy: The Advantages of Stent Placement. Journal of Vascular and Interventional Radiology, 2013, 24, 370-377.	0.5	10
195	Recent temporal trends for first-time hospitalization for acute myocardial infarction. Treatment patterns and clinical outcome in a large cohort study. American Heart Journal, 2013, 166, 846-854.	2.7	10
196	Long-term Follow up of Patients with Acute Aortic Syndromes: Relevance of both Aortic and Non-aortic Events. European Journal of Vascular and Endovascular Surgery, 2018, 56, 200-208.	1.5	10
197	Risk Stratification of Patients With Classic Angina Pectoris and No History of Coronary Artery Disease by Dobutamine Stress Echocardiography. Journal of the American College of Cardiology, 2005, 46, 730-732.	2.8	9
198	Heart transplantation in infants with idiopathic hypertrophic cardiomyopathy. Pediatric Transplantation, 2009, 13, 650-653.	1.0	9

#	Article	IF	Citations
199	Trialâ€generated profiles for implantation of electrical devices in outpatients with heart failure: realâ€world prevalence and 1â€year outcome. Journal of Evaluation in Clinical Practice, 2010, 16, 82-91.	1.8	9
200	Acute heart failure in patients with acute aortic syndrome: pathophysiology and clinicalâ€“prognostic implications. European Journal of Heart Failure, 2015, 17, 917-924.	7.1	9
201	Relation between thoracic aortic inflammation and features of plaque vulnerability in the coronary tree in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. An FDG-positron emission tomography and optical coherence tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1878-1887.	6.4	9
202	Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis. International Journal of Cardiology, 2020, 307, 187-192.	1.7	9
203	Hypertrophic cardiomyopathy with massive hypertrophy, amiodarone treatment and high defibrillation threshold at cardioverterâ€“defibrillator implant. International Journal of Cardiology, 2002, 83, 171-173.	1.7	8
204	Prognostic stratification of patients with right bundle branch block using dobutamine stress echocardiography. American Journal of Cardiology, 2004, 94, 954-957.	1.6	8
205	Effects of cardiac resynchronization therapy on right ventricular function during rest and exercise, as assessed by radionuclide angiography, and on NT-proBNP levels. Journal of Nuclear Cardiology, 2019, 26, 123-132.	2.1	8
206	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€”Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2022, 28, e1-e4.	1.7	8
207	Late Improvement in Ventricular Performance Following Internal Cardioversion for Persistent Atrial Fibrillation:. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 1218-1226.	1.2	7
208	Interventricular Delay Optimization: A Comparison among Three Different Echocardiographic Methods. Echocardiography, 2010, 27, 38-43.	0.9	7
209	The empowerment of translational research: lessons from laminopathies. Orphanet Journal of Rare Diseases, 2012, 7, 37.	2.7	7
210	Understanding the results of the PARAGONâ€HF trial. European Journal of Heart Failure, 2020, 22, 1531-1535.	7.1	7
211	Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Cardiology and Therapy, 2022, 11, 393-405.	2.6	7
212	Title is missing!. Coronary Artery Disease, 2003, 14, 239-245.	0.7	6
213	Etiology of Amyloidosis Determines Myocardial 99mTc-DPD Uptake in Amyloidotic Cardiomyopathy. Clinical Nuclear Medicine, 2015, 40, 446-447.	1.3	6
214	Prognostic significance of shockable and non-shockable cardiac arrest in ST-segment elevation myocardial infarction patients undergoing primary angioplasty. Resuscitation, 2018, 123, 8-14.	3.0	6
215	Cardiac implantable electrical devices in patients with hypertrophic cardiomyopathy: single center implant data extracted from the Swedish pacemaker and ICD registry. Scandinavian Cardiovascular Journal, 2020, 54, 239-247.	1.2	6
216	Diastolic dysfunction, frailty and prognosis in elderly patients with acute coronary syndromes. International Journal of Cardiology, 2021, 327, 31-35.	1.7	6

#	Article	IF	Citations
217	Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle?. European Journal of Heart Failure, 2021, 23, 259-263.	7.1	6
218	Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice. European Journal of Internal Medicine, 2021, 90, 10-15.	2.2	6
219	Radionuclide Angiographic Determination of Regional Left Ventricular Systolic Function During Rest and Exercise in Patients With Nonischemic Cardiomyopathy Treated With Cardiac Resynchronization Therapy. American Journal of Cardiology, 2010, 106, 389-394.	1.6	5
220	What is the acceptable rate of false positives for STEMI within a primary PCI network? Insights from a metropolitan system with direct ambulance-based access. International Journal of Cardiology, 2012, 154, 356-358.	1.7	5
221	Massive Pulmonary Embolism with Acute Coronary Syndrome-like Electrocardiogram Mimicking Acute Left Main Coronary ArteryÂObstruction. Journal of Emergency Medicine, 2012, 43, e255-e258.	0.7	5
222	Risk of Stroke in Patients With High On-Clopidogrel Platelet Reactivity to Adenosine Diphosphate After Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 113, 1807-1814.	1.6	5
223	Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 173-181.	3.0	5
224	Clinical Use of Doppler Echocardiography in Organic Mitral Regurgitation: From Diagnosis to Patients' Management. Journal of Cardiovascular Imaging, 2015, 23, 121.	0.8	4
225	Predictors of nonsimultaneous interventricular delay at cardiac resynchronization therapy optimization. Journal of Cardiovascular Medicine, 2016, 17, 299-305.	1.5	4
226	Primary Cardiac Leiomyoma Causing Right Ventricular Obstruction and Tricuspid Regurgitation. Annals of Thoracic Surgery, 2017, 104, e231-e233.	1.3	4
227	The complex interplay between systolic and diastolic function at rest and during exercise in heart failure: the case of cardiac amyloidosis. European Journal of Heart Failure, 2017, 19, 1466-1467.	7.1	4
228	Postmortem diagnosis of left dominant arrhythmogenic cardiomyopathy: the importance of a multidisciplinary network for sudden death victims. â€œHIC mors gaudet succurere vitaeâ€• Cardiovascular Pathology, 2020, 44, 107157.	1.6	4
229	A new therapy for transthyretin amyloidosis, no longer an orphan condition. European Heart Journal Supplements, 2020, 22, E125-E131.	0.1	4
230	The Combination of Chest Computed Tomography and Standard Electrocardiogram Provides Prognostic Information and Pathophysiological Insights in COVID-19 Pneumonia. Journal of Clinical Medicine, 2021, 10, 3031.	2.4	4
231	Female Sex as a Possible Protective Factor From Myocardial Involvement in Transthyretin-Related Amyloidoses. Archives of Internal Medicine, 2005, 165, 2429.	3.8	3
232	Age and heart transplantation: results from a heart failure management unit. Clinical Transplantation, 2008, 22, 150-155.	1.6	3
233	Prenatal echographic recognition of hypertrophic cardiomyopathy leading to heart transplantation in the newborn. European Heart Journal, 2008, 29, 845-845.	2.2	3
234	Incidence, treatment and outcome of acute coronary syndromes: A community-based study in the era of myocardial infarction networks. International Journal of Cardiology, 2012, 157, 419-422.	1.7	3

#	Article	IF	Citations
235	Predictors of complicated athero-thrombotic lesions in non-ST segment acute coronary syndrome. Journal of Cardiovascular Medicine, 2013, 14, 430-437.	1.5	3
236	Prognostic stratification and treatment of cardiac light chain amyloidosis: A narrow path in the jungle. Journal of Heart and Lung Transplantation, 2014, 33, 136-138.	0.6	3
237	A targeted proteomics approach to amyloidosis typing. Clinical Mass Spectrometry, 2018, 7, 18-28.	1.9	3
238	The complex interplay between fitness, genetics, lifestyle, and inflammation in the pathogenesis of coronary atherosclerosis: lessons from the Amazon rainforest. European Heart Journal Supplements, 2019, 21, B76-B79.	0.1	3
239	The â€˜Black Deathâ€™ and the physician at the time of COVID-19. European Heart Journal, 2020, 41, 3501-3502.	2.2	3
240	Safety and efficacy of levosimendan in patients with cardiac amyloidosis. European Journal of Internal Medicine, 2020, 80, 114-116.	2.2	3
241	Phenotypic heterogeneity of COVIDâ€19 pneumonia: clinical and pathophysiological relevance of the vascular phenotype^a. ESC Heart Failure, 2022, 9, 263-269.	3.1	3
242	Impact of cardiac amyloidosis on outcomes of patients hospitalized with heart failure. European Journal of Internal Medicine, 2022, 102, 88-96.	2.2	3
243	Obstructive intramural coronary amyloidosis: a distinct phenotype of cardiac amyloidosis that can cause acute heart failure. European Heart Journal, 2006, 27, 1810-1810.	2.2	2
244	Local Amyloidosis as a Possible Component of the Atrial Remodeling Accompanying Trial. Journal of the American College of Cardiology, 2008, 51, 2444-2445.	2.8	2
245	â€œMy Parents Died of Myocardial Infarction: Is that My Destiny?â€• Medical Clinics of North America, 2012, 96, 67-86.	2.5	2
246	Broadening the Phenotypic Spectrum andÂthe Diagnostic Needs of TTR-Related Cardiac Amyloidosis â^—. Journal of the American College of Cardiology, 2017, 70, 478-480.	2.8	2
247	Atrial Flutter in Patient With Critical COVID-19. JACC: Case Reports, 2021, 3, 162-164.	0.6	2
248	The labyrinth of nomenclature in Cardiology. Eternal dilemmas and new challenges on the horizon in the personalized medicine era. European Journal of Heart Failure, 2021, 23, 1062-1067.	7.1	2
249	Performance of Synthetic Extracellular Volume Fraction in Different Cardiac Phenotypes From a Prospective Cohort of Patients Referred for Cardiac Magnetic Resonance. Journal of Magnetic Resonance Imaging, 2021, 54, 429-439.	3.4	2
250	Left Ventricular Myocardial Noncompaction with Advanced Atrioventricular Conduction Disorder and Ventricular Arrhythmias in a Young Patient: Role of MIB1 Gene. Journal of Cardiovascular Development and Disease, 2021, 8, 109.	1.6	2
251	Diagnosis of idiopathic restrictive cardiomyopathy at a glance. Journal of Cardiovascular Medicine, 2007, 8, 758.	1.5	1
252	Aortic thrombosis: a shared complication of different underlying diseases. Journal of Cardiovascular Medicine, 2007, 8, 967-968.	1.5	1

#	Article	IF	Citations
253	Amyloidosis. Also a Heart Disease. Revista Espanola De Cardiologia (English Ed), 2011, 64, 797-808.	0.6	1
254	An unusual case of a congenital aorto-left atrial tunnel. Cardiovascular Pathology, 2014, 23, 241-243.	1.6	1
255	Late gadolinium enhancement score (LGE-Score) for prediction of extensive late gadolinium enhancement in hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2015, 17, Q59.	3.3	1
256	The left atrium in cardiac amyloidosis: a valuable but still underused observation window on the overall disease process. European Journal of Heart Failure, 2021, 23, 1296-1299.	7.1	1
257	Inotropic therapy is unsuccessful: wrong conceptual target or wrong therapeutic tools?. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2003, 4 Suppl 2, 22S-26S.	0.1	1
258	351â€ƒPrevalence and prognostic significance of RV uptake (biventricular uptake) at planar scintigraphy in patients with ATTR cardiac amyloidosis. European Heart Journal Supplements, 2021, 23, .	0.1	1
259	Radionuclide evaluation of ventricular function at rest and during exercise in double inlet ventricle. International Journal of Cardiology, 1989, 23, 99-104.	1.7	0
260	Ventricular fibrillation during sleep in an adolescent with hypertrophic cardiomyopathy: the difficulty of risk stratification and the power of the cardioverter-defibrillator. International Journal of Cardiology, 2004, 97, 143-144.	1.7	0
261	The Mediterranean diet: a cultural journey â€“ Authors' reply. Lancet, The, 2011, 378, 767.	13.7	0
262	An unusual case of familial hypertrophic cardiomyopathy with left ventricular systolic dysfunction: a still unsolved diagnosis. Neurology International, 2012, 2, 8.	0.5	0
263	Prognostic Significance of Baseline White Blood Cell Count in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. Cardiology, 2013, 125, 90-91.	1.4	0
264	Cardiac FDG PET/CT is useful to assess the culprit lesion in nonST-segment elevation myocardial infarction (NSTEMI). European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 642-643.	6.4	0
265	Myocardial amyloid infiltration: a less than expected homogeneous process. Heart, 2014, 100, 1659-1660.	2.9	0
266	Reactive follicular lymphoid infiltrate: A new condition to exclude in patients with PET positivity inside the heart. Journal of Nuclear Cardiology, 2014, 21, 402-405.	2.1	0
267	Imaging Myocardium at Risk and Coronary Inflammation in Nonâ€“ST-Segment Elevation Myocardial Infarction. Clinical Nuclear Medicine, 2015, 40, e61-e62.	1.3	0
268	ASSESSMENT OF MITRAL REGURGITATION THROUGH DOPPLER ECHOCARDIOGRAPHY: FEASIBILITY, PITFALLS AND DIAGNOSTIC ADVANTAGES. Journal of Mechanics in Medicine and Biology, 2015, 15, 1540011.	0.7	0
269	Heart rate modulation in stable coronary artery disease without clinical heart failure: What we have already learned from SIGNIFY?. Contemporary Clinical Trials Communications, 2016, 4, 58-63.	1.1	0
270	Extracardiac imaging in amyloidosis: A long and winding (but possible) road. International Journal of Cardiology, 2018, 254, 351-352.	1.7	0

#	Article	IF	Citations
271	A Pathogenic Galactosidase A Mutation Coexisting With an MYBPC3 Mutation in a Female Patient With Hypertrophic Cardiomyopathy. Canadian Journal of Cardiology, 2020, 36, 1554.e1-1554.e3.	1.7	0
272	The cardiologist and myocardial and pericardial diseases: a cultural, clinical, organizational challenge. Minerva Cardiology and Angiology, 2021, , .	0.7	0
273	Familial Cardiac Amyloidoses. , 2018, , 545-577.		0
274	465â€ƒUnmasking the prevalence of cardiac amyloidosis in the real world: first insights from the phase 2 of active study, an Italian nationwide survey. European Heart Journal Supplements, 2021, 23, .	0.1	0
275	407 Phenotypic heterogeneity of COVID-19 pneumonia: clinical and phatophysiologic relevance of the vascular phenotype. European Heart Journal Supplements, 2021, 23, .	0.1	0